Vildagliptin Prices Fall By Over 70% In India Post Patent Expiry
Novartis Sells Vildagliptin Brand To USV, Cipla Explores Talks
Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla
